Chairman of the Board of NorDiag ASA, Robert V. Ahlgren has today purchased 60
000 shares at an average price of NOK 1,68. New holding of NorDiag shares after
the transaction is 161 496.
Vice Chairman of the Board of NorDiag ASA, Hans Hekland has through his wholly
owned investment company Hannibal Invest today purchased 120 000 shares at an
average price of NOK 1,68. New holding of NorDiag shares after the transaction
is 391 004.
CEO of NorDiag ASA, Mårten Wigstøl has through his wholly owned investment
company Barracuda Invest today purchased 60 000 shares at an average price of
NOK 1,68. New holding of NorDiag shares after the transaction is 165 815.
Contact:
CFO Tone Kvåle, phone +47 915 19576
About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing
automated solutions (instruments and tests) for sample preparation of DNA from
difficult biological samples. DNA diagnostics give more rapid and precise
answers, and is the fastest growing field within diagnostics. The company's
sample preparation solutions are today used in connection with STI,
tuberculosis, MRSA, respiratory pathogens and viruses on instruments for large
and small laboratories. NorDiag was founded in 2003 and has its headquarters in
Oslo, Norway. The company has offices and laboratories in Stockholm, Sweden, in
West Chester (PA), USA and in Vienna, Austria. The group has today 40.1
man-labour years. NorDiag is listed on Oslo Stock Exchange with ticker NORD.
For further information, please see www.nordiag.com.
This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)
[HUG#1376210]
